Atara Biotherapeutics, Inc.
2659 Townsgate Road
Suite 236
Thousand Oaks
California
91361
United States
Tel: 805-309-0888
Website: http://www.atarabio.com/
87 articles with Atara Biotherapeutics, Inc.
-
Clinical Catch-Up: September 9-13
9/16/2019
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories. -
ATARA BIOTHERAPEUTICS TO PRESENT INITIAL EFFICACY AND ADDITIONAL SAFETY RESULTS FROM PHASE 1 STUDY OF ATA188 IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS AT ECTRIMS 2019
9/9/2019
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced it will present for the first time initial efficacy data as well as updated safety results from its ongoing Phase 1 study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS) in a late-breaking poster presentation at the 35thCongress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
-
ATARA BIOTHERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS
8/8/2019
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the second quarter of 2019 and recent operational highlights.
-
ATARA BIOTHERAPEUTICS TO ANNOUNCE SECOND QUARTER 2019 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON THURSDAY, AUGUST 8, 2019
8/1/2019
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that its second quarter 2019 financial results will be released before the market opens on Thursday, August 8, 2019.
-
Atara Biotherapeutics Announces Pricing of $150.0 Million Public Offering
7/18/2019
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the pricing of an underwritten public offering of 6,871,727 shares of its common stock at a price to the public of $15.28 per share.
-
Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year
7/16/2019
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced an updated development plan for the Phase 3 tab-cel® (tabelecleucel) program for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD).
-
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
-
This year could be the big year for the company. Its chief executive officer and president, Isaac Ciechanover, is leaving the company by June 30, but says 2019 could be transformative.
-
BioSpace Movers and Shakers: Jan. 4
1/4/2019
Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more. -
Atara Biotherapeutics Exclusively Licenses Mesothelin-Targeted CAR T Immunotherapy for Solid TumorsAtara Biotherapeutics Exclusively Licenses Mesothelin-Targeted� CAR T Immunotherapy for Solid Tumors
1/3/2019
Initial results from ongoing Phase 1 study for mesothelin-targeted CAR T support activity and safety in patients with advanced solid tumors
-
BioSpace Movers and Shakers for Oct. 15
10/15/2018
Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies. -
Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies
9/10/2018
Focus on multi-targeted CAR T immunotherapies for patients with acute myelogenous leukemia (AML) and B-cell malignancies
-
There is a new player in the southern California biotech industry. New venture firm Westlake Village BioPartners launched with a $320 million fund and a leadership well familiar with the ins and outs of the biotech and pharma world.
-
Hiring Roundup of Biotech Leaders
5/13/2018
Biotech companies tapped a number of new upper management and c-suite executives last week. BioSpace put together a roundup of some of the latest appointments in the industry, which includes a number of new chief executive officers hired to helm companies. -
With the J.P. Morgan Healthcare Conference now over, some analysts are looking back and picking out the "winners and losers" from the conference.
-
Atara Biotherapeutics Announces FDA Clearance to Proceed With Enrollment at U.S. Sites for Ongoing Global Phase I Clinical Study to Evaluate ATA188 in Patients With Progressive or Relapsing-Remitting Multiple Sclerosis
1/10/2018
The primary objective of Atara’s ongoing Phase 1 clinical study is to assess the safety of ATA188 in patients followed for at least one year after the first dose.
-
Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
1/4/2018
The offering is expected to close on or about January 8, 2018, subject to customary closing conditions.
-
Atara Biotherapeutics Announces Proposed Offering of Common Stock - Jan. 2, 2018
1/2/2018
The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
-
Atara Biotherapeutics Announces Initiation of Two Phase III Clinical Studies to Evaluate Tabelecleucel in Patients With Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)
1/2/2018
Tabelecleucel is Atara's off-the-shelf T-cell immunotherapy in development for the treatment of EBV+PTLD, as well as other EBV associated hematologic and solid tumors.
-
Atara Biotherapeutics to Host Corporate Update Conference Call on Friday, December 29, 2017, at 8:00 a.m. EST
12/29/2017
A replay of the webcast will be available on the Company’s website for 90 days following the live conference call.